A comparison of response to cisplatin, radiation and combined treatment for cells deficient in recombination repair pathways

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 53-58

  Raaphorst, G P ^a   Leblanc, J Maude ^a   Li, L F ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cisplatin; DNA repair; Mutants; Radiation; Recombination repair

Indexed keywords

CISPLATIN; RAD54 PROTEIN;

ANIMAL CELL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL LINE; CHICKEN; CHO CELL; CONTROLLED STUDY; DNA RECOMBINATION; DNA REPAIR; DRUG RESPONSE; EMBRYO CELL; FIBROBLAST; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANIMALS; ANTIGENS, NUCLEAR; CELL LINE; CHICKENS; CHO CELLS; CISPLATIN; CRICETINAE; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; RADIATION TOLERANCE; RECOMBINATION, GENETIC;

EID: 16344382929     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sledge GW: Cisplatin and platinum analogues in breast cancer. Semin Oncol 19: 78-82, 1992.
2. Piver MS: Ovarian carcinoma, a decade of progress. Cancer 54: 2706-2715, 1984.
3. Taylor SG, Murphy AK, Vannetzel JM et al: Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12: 385-395, 1994.
4. Palazzi M, Calaldo I, Gramaglia A, de Toma D, Milani F and Ravasi G: Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. Int J Rad Oncol 27: 621-625, 1993.
5. Zietman AL, Shipley WU and Kaufman DS: The combination of cisplatin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. Int J Rad Oncol 27: 161-170, 1993.
6. Kelland LR: Cisplatin-based anticancer agents. In: Uses of Inorganic Chemistry in Medicine. Ed. Farrell NP. pp. 109-134, 1999.
7. Wen H, Zu JY, Lin L and Li T: Nasopharyngeal carcinoma (NPC) treated by hyperfractionated irradiation plus alternating chemotherapy. Radiother Oncol 43: 587, 1997.
8. Teicher BA: The role of platinum complexes in combined modality therapy. In: Chemoradiation in Cancer Therapy. Ed. Choy H. Humana Press, Totowa New Jersey, pp. 47-63, 2003.
9. Canal P: Platinum compounds: pharmacokinetics and pharmacodynamics. In: A Clinician's Guide to Chemotherapy, Pharmacokinetics and Pharmacodynamics Eds. Grochow LB and Ames MM, Williams and Wilkins, Baltimore, pp. 345-373, 1998.
10. Dewit L: Combined treatment of radiation and cis-disminedichloroplatinum (II): A review of experimental and clinical data. Int J Rad Oncol 13: 403-426, 1987.
11. Calsou P and Salles B: Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol 32: 85-89, 1993.
12. Sancar A and Sancar GB: DNA repair enzymes. Ann Rev Biochem 57: 29-67, 1988.
13. Sibghat-Ullah, Intinsar H, Carleton W and Sancar A: Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract. Nuclear Acids Res 17: 4471-4484, 1989.
14. Korberle B, Masters JR, Hartley JA and Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Current Biol 9: 273-276, 1999.
15. Zhen W, Evans MK, Haggerty CM and Bohr VA: Deficient gene specific repair of cisplatin lesions in XP and FA cell lines. Carcinogenesis 14: 919-924, 1993.
16. Tanaka K, Nakatsu Y, Sayo M, Kuraoka I, Matsuda T, Kobayashi T, Murai H and Nakane H: Nucleotide excision repair defect and carcinogenesis in XPA-knocked out mice. J Cell Mol Biochem, Supplement 21A: 272, 1995.
17. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bruton FB and Reed E: Association between the level of ERCC expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000.
18. Zdraveski ZZ, Mello JA, Marinus MG and Essigmann JM: Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 7: 39-50, 2000.
19. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, Brookman KW, Siciliano MJ, Walter CA, Fan W, Narayana LS, Zhou ZQ, Adamson AW, Sorensen KJ, Chen DJ, Jones NJ and Thompson LH: XRCC2 and XRCC3 new human Rad 51-family members promote chromosome stability and protect against DNA cross links and other damages. Mol Cell 1: 783-793, 1998.
20. Pierce AJ, Johnson RD, Thompson LH and Jasin M: XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Develop 13: 2633-2638, 1999.
21. Burgman P, Ouyang H, Peterson S, Chen DJ and Li GC: Heat inactivation of Ku autoantigen: possible role in hyperthermic radiosensitization. Cancer Res 57: 2847-2850, 1997.
22. Myint WK, Ng C and Raaphorst GP: Examining the non-homologous repair process in cisplatin and radiation treatments. Int J Rad Biol 78: 417-424, 2002.
23. Sobol RW, Norton JK, Kuhn R et al: Requirement of mammalian DNA polymerase β in base excision repair. Nature 579: 183-186, 1996.
24. Frosina G, Fortini P, Rossi O, Carrozzino F, Raspaglio G, Cox LS, Lane DP, Abbondandolo A and Dogliotti E: Two pathways for base excision repair in mammalian cells. J Biol Chem 271: 9573-9578, 1996.
25. de Vries A and van Sleeg H: XPA knockout mice. Cancer Biol 7: 229-240.
26. Hoeijmakers JHJ: Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer 30A: 1912-1921, 1994.
27. Liang F, Han M, Romanienko PJ and Jasin M: Homology directed repair a major repair pathway in mammalian cells. Proc Nat Acad Science 95: 5172-5177, 1998.
28. Wachsberge PR, Li WH, Guo M, Chen D, Cheong N, Ling CC, Li G and Iliakis G: Rejoining of DNA double strand breaks in Ku80-deficient mouse fibroblasts. Radiation Res 151: 398-407, 1999.
29. Utsumi H, Tano K, Takata M, Takeda S and Elkind MM: Requirement for repair of DNA double strand breaks by homologous recombination in split-dose recovery. Radiation Res 155: 68-686, 2001.
30. Takata M, Sasaki MS, Sonoda E, Monison C, Hasimoto M, Utsumi H, Yamaguchi Y, Wai I, Shinohara A and Takeda S: Homologous recombination and nonhomologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17: 5497-5508, 1998.
31. Dolling JA, Boreham DR, Brown DL, Raaphorst GP and Mitchell REJ: Cisplatin modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cervisiae. Mutation Res 433: 127-136, 1999.
32. Takata M, Sasoki M, Sonada E, Fukushima T, Morisson C, Albala JS, Swagemakers SMA, Kanaar R, Thompson LH and Takeda S: Rad 51 Paralog Rad 51B promotes homologous recombination repair. Mol Cell Biol 20: 6476-6482, 2000.
33. Raaphorst GP, Wang G and Ng CE: Radiosensitization by cisplatin treatment in cisplatin resistant and sensitive human ovarian carcinoma cell lines. Int J Oncol 7: 325-330, 1995.
34. Raaphorst GP, Wang G, Stewart DJ and Ng CE: Concomitant low dose rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Int J Rad Biol 69: 623-631, 1996.
35. Douple EB: Interaction between cisplatin coordination complexes and radiation. In: Hill BT, Bellamy AS, eds. Antitumour Drug-radiation Interactions. Boca Raton, Florida: CRC Press 171-190, 1990.
36. Wilkins DE, Ng CE and Raaphorst GP: Cell cycle perturbations in cisplatin sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation. Cancer Chemother Pharmacol 40: 159-166, 1995.
37. Wilkins DE, Raaphorst GP and Heller DP: Inhibition of potentially lethal damage recovery by cisplatin in the 9L rat brain cell line. Anticancer Res 13: 2137-2142, 1993.
38. Dolling JA, Boreham DR, Brown DL, Mitchell REJ and Raaphorst GP: Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int J Rad Biol 74: 61-69, 1998.